Archives

Law: Psychedelic Drugs for Mental Health Disorders: Clinical and Legal Issues

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

Learning Objectives

·       Describe the important features of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) with commonly employed non-pharmacologic and pharmacologic treatments
·       Identify the pharmacologic features of MDMA and psilocybin and clinical trial results when applied to patients with mental health disorders
·       Describe legal barriers to using psychedelics in patients with mental health disorders and ways to circumvent them at a national or state level

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-017-H03-P

Session Code

22SR17-ABC28

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
Professor and Department Head Pharmacy Practice
University of Connecticut School of Pharmacy and Director HOPES Research Group
Storrs, CT

Faculty Disclosure

Dr. White has no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test Pharmacist

Herbal/Drug Interactions in Cancer Care

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation discusses how herbal medications can impact cancer treatment.

Learning Objectives

·       Describe various formulations of herbal products
·       Compare complimentary versus alternative medicine
·       Describe different mechanisms of pharmacokinetic and pharmacodynamic based herb drug interactions
·       Identify common herb / chemotherapy interactions
·       Name helpful resources for a pharmacist to investigate these interactions

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-018-H01-P

Session Code

22SR18-CBA96

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-018-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Rebecca Briana Shamilov, PharmD., BCOP
Senior Oncology Pharmacist
Education & Training, Smilow Cancer Center
New Haven, CT

Faculty Disclosure

Dr. Shamilov has no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test Pharmacist

1. How does the medical community usually define complementary medicine?
A. Medicine used with standard treatment but not considered standard treatment by itself
B. Medicine used instead of standard medical treatment
C. Medicine at no cost –it’s complementary!

2. Which aspect of pharmacokinetics is St. John’s Wort known to alter in patients who are taking imatinib?
A. Absorption–by affecting gastric pH
B. Metabolism–by increasing drug clearance
C. Distribution–by competing with albumin binding sites

3. With respect to the gastrointestinal tract, how do orally administered herbs interact with prescription medication for cancer?
A. They may alter motility, gastric pH, and P-gycoprotein transport
B. They may alter motility, gastric pH, and CYP enzyme activity
C. They may alter the peritoneal space, sodium levels, and P-GP transport

4. Which of the following complementary medications used for hot flashes MAY be a problem in a woman taking tamoxifen?
A. St. John’s wort
B. Echinacea
C. Black cohash

5. Which of the following references contains monographs, an adverse effects checker and a tool to check interactions with hormone sensitive diseases such as breast cancer.?
A. Sloan Kettering Cancer Center’s About Herbs database
B. Natural Medicines Comprehensive Database
C. NIH’s Herbs at a Glance fact sheet

Addiction Pharmacology and Ibogaine

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation discusses Ibogaine and its potential use in addiction treatment.

Learning Objectives

1.    Review the history of iboga, ibogaine, and available forms
2.    Describe pharmacological properties of ibogaine
3.    List contraindicated drugs and conditions with ibogaine
4.     Discuss pharmacologic mechanisms and candidates for ibogaine use

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-019-H01-P

Session Code

22SR19-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-019-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Benjamin Malcolm, PharmD., MPH
Psychopharmacology Consultant
Spirit Pharmacist LLC
Eugene OR

Faculty Disclosure

Dr. Malcolm has no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test Pharmacist

1. Which of the following is TRUE of ibogaine?
A. It was synthesized by researchers in Japan during the early 1900s
B. It is a naturally occurring alkaloid derived from Tabernanthe iboga
C. It is extracted from the iboga root that is native to South America

2. Which of the following is TRUE regarding the pharmacology of ibogaine?
A. It has a long-acting metabolite called noribogaine
B. Its pharmacokinetic profile is remarkably simple
C. It binds exclusively to the opioid receptor

3. In which condition would ibogaine be contraindicated?
A. Allergic rhinitis
B. Pancreatic cancer
C. Prolonged baseline QTc interval

4. Which of the following is a pharmacologic effect of ibogaine supported by observational research?
A. Detoxification of heroin use disorder
B. Detoxification of alcohol use disorder
C. Detoxification of SSRI overdose

5. Which adverse effect has been reported with ibogaine use?
A. Serotonin toxicity
B. Neuroleptic malignant syndrome
C. Ventricular arrythmias

From the Mouths of Snakes: ACE Inhibitors

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation discusses Ace Inhibitors.

Learning Objectives

 1. Review pharmacological hypertension management history and ACE inhibitor discovery
2. Analyze ACE inhibitor mechanism of action and hypertension pathophysiology
3. Investigate approved and off-label uses of ACE inhibitors
4. Characterize ongoing ACE inhibitor research and potential benefits and uses

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-020-H01-P

Session Code

22SR20-VXK92

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-020-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Alexandra Bieniek,
2022 PharmD Candidate
UConn School of Pharmacy
Storrs, CT

and

Jeannette Y. Wick, RPh, MBA FASCP
Director OPPD
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

Alexandra Bienieck and Jeannette Wick have no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test Pharmacist

1. How do ACE inhibitors work?
A. They convert angiotensin I to angiotensin II
B. They convert renin to angiotensin II
C. They convert Angiotensin II to angiotensin I

2. Before ACE inhibitors were marketed, what drugs were the mainstay of treatment for hypertension?
A. Injectable diuretics, especially furosemide
B. Oral diuretics, and especially chlorthalidone
C. Surgical interventions

3. Which of the following are FDA-approved uses for many ACE inhibitors?
A. Heart failure, hypertensive emergencies, MI and/or stroke prophylaxis
B. Heart Failure, hypertensive emergencies, MI and pancreatic cancer
C. Heart Failure, hypertensive emergencies, MI and sarcopenia

4. Which of the following indications are under investigation for ACE inhibitors?
A. Hepatic necrosis, oligospermia, and sarcopenia
B. Raynaud’s syndrome, sarcopenia, and oligospermia
C. Oligospermia, Raynaud’s syndrome, and sarcopenia.

5. In most conditions in which ACE inhibitors are being investigated but are not yet approved, what is the value of these drugs?
A. We have no treatments for many of these conditions, so ACE inhibitors would be valuable first-line options for people who are suffering
B. Many of these conditions have preferred treatments, ACE inhibitors may be valuable second- or third-line options for refractory cases
C. Many of these conditions have preferred treatments, but ACE inhibitors would replace the first-line treatments with fewer side effect

Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

Learning Objectives

1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in
psychiatry, with an emphasis on psilocybin.
2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal
status.
3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

Session Offered

Released:  April 27, 2023
Expires:  April 27, 2026

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-23-011-H03-P

Session Code

23RW11-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Gerald Gianutsos, PhD, JD,
Professor Emeritus
University of Connecticut School of Pharmacy
Storrs, CT 

Faculty Disclosure

Dr. Gianutsos has no financial relationships with any ineligible company associated with this presentation.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test Pharmacist

Schwarting Webinar 2023 Post-Test

 

    1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
    2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
    3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

 

The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

 

  1. Serotonin
  2. Dopamine
  3. Glutamate

 

 

The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

  1. Schizophrenia
  2. Treatment resistant depression
  3. Post traumatic stress disorder

 

 

 

Which feature distinguishes a C-I drug from other controlled substances?

  1. High potential for abuse, especially among hi-riskpopulations
  2. Lack of accepted safety for use under medical supervision
  3. No currently accepted medical use in treatment in the United States

 

 

Which state was the first to approve the use of psilocybin for medical use?

  1. California
  2. Oregon
  3. Maryland

 

 

A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

  1. Use of psychedelic therapy is time-and resource-intensive
  2. Requires multiple treatments with a slow onset of activity
  3. There is a high risk of autonomic side effects and addiction

 

 

In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

  1. Psilocybin can be purchased at retail outlets including pharmacies
  2. Psilocybin is available from any therapist throughout the state
  3. Psilocybin is only available in state licensed clinics